NCT06877390 (EECP) is a NA clinical trial of conventional drug and exercise rehabilitation in Enhanced External Counterpulsation (EECP), sponsored by Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences.

What drugs are being tested in NCT06877390?

Interventions in NCT06877390: conventional drug and exercise rehabilitation, EECP-based rehabilitation regimen.

What condition does NCT06877390 study?

NCT06877390 studies Enhanced External Counterpulsation (EECP), Acute Myocardial Infarction (AMI), Drug-coated Balloon, Cardiac Rehabilitation.

Is NCT06877390 still recruiting?

NCT06877390 is currently completed. Last updated 14 March 2025.

Last reviewed 2025-03-14 · How we verify

NCT06877390: EECP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Enhanced External Counterpulsation

Completed NA Last updated 14 March 2025

What this trial tests

NA trial testing conventional drug and exercise rehabilitation in Enhanced External Counterpulsation (EECP) in 60 participants. Completed in 30 April 2024.

Timeline

1 November 2023

Primary endpoint
30 April 2024

30 April 2024

Quick facts

Lead sponsor	Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	60
Start date	1 November 2023
Primary completion	30 April 2024
Estimated completion	30 April 2024
Sites	1 location across China

Drugs / interventions tested

conventional drug and exercise rehabilitation
EECP-based rehabilitation regimen

Conditions studied

Enhanced External Counterpulsation (EECP) — all drugs for Enhanced External Counterpulsation (EECP) →
Acute Myocardial Infarction (AMI) — all drugs for Acute Myocardial Infarction (AMI) →
Drug-coated Balloon — all drugs for Drug-coated Balloon →
Cardiac Rehabilitation — all drugs for Cardiac Rehabilitation →

Sponsor

Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences

Who can join

Adults 18 to 75, any sex, with Enhanced External Counterpulsation (EECP) or Acute Myocardial Infarction (AMI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluated the efficacy and safety of enhanced extracorporeal counterpulsation for cardiac rehabilitation in patients after DCB for acute myocardial infarction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06877390 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences
Last refreshed: 14 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06877390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing